

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7778191

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	TG THERAPEUTICS, INC.	01/30/2023
RECEIVING PARTY DATA		
Name:	LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES	
Street Address:	3 AVENUE DES TROPIQUES	
City:	LES ULIS	
State/Country:	FRANCE	
Postal Code:	91940	
PROPERTY NUMBERS Total: 4		
Property Type	Number	
Application Number:	17892407	
Application Number:	17892460	
Application Number:	17892465	
Application Number:	63347852	
CORRESPONDENCE DATA		
Fax Number:	(877)769-7945	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	+1 (617) 521-7023	
Email:	apsi@fr.com	
Correspondent Name:	PALLAVI BANERJEE	
Address Line 1:	FISH & RICHARDSON P.C.	
Address Line 2:	P.O.BOX 1022	
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022	
ATTORNEY DOCKET NUMBER:	50581-0004001-0003	
NAME OF SUBMITTER:	MARY FLORCZAK	
SIGNATURE:	/Mary Florczak/	
DATE SIGNED:	02/03/2023	
Total Attachments: 2		
source=TGTx_-_Joint_Assignment#page1.tif		

JOINT ASSIGNMENT OF RIGHTS

WHEREAS, TG Therapeutics, Inc., having a principal place of business at 2 Gansevoort Street, 9th Floor, New York, NY 10014, is an owner of an undivided share of the entire right, title and interest in and to the following patent applications, and the inventions and improvements described therein:

- United States patent application No. 17/892,460, filed on August 22, 2022;
- United States patent application No. 17/892,465, filed on August 22, 2022;
- United States patent application No. 17/892,407, filed on August 22, 2022, and
- United States patent application No. 63/347,852, filed on June 1, 2022.

all of which are entitled "ANTI-CD20 ANTIBODY COMPOSITIONS"


AND WHEREAS, TG Therapeutics, Inc. wishes to assign to the Laboratoire Francais du Fractionnement et des Biotechnologies, having a place of business at 3 Avenue Des Tropiques Les Ulis, FRANCE, 91940, a joint and equal share in and to the inventions described in the above patent applications, and the inventions and improvements described therein;

NOW, for good and valuable consideration, TG Therapeutics, Inc. hereby assigns to Laboratoire Francais du Fractionnement et des Biotechnologies, their successors and assigns, as joint and equal owners with TG Therapeutics, Inc. of the entire right, title and interest throughout the world, this assignment including said applications, and the inventions and improvements described therein, any and all United States and foreign patents, utility patents and models, continuations, continuations-in-part, divisionals, reexaminations, reissues, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said applications under all treaties; and this assignment also including, without limitation, any claims (known or unknown, suspected or unsuspected) of any nature that TG Therapeutics, Inc. has or may have against any party for infringement of any of the patent applications listed herein and any United States or foreign patents that issue therefrom, and the right to sue for past infringement and to recover and retain damages and profits in respect thereof; and

TG Therapeutics, Inc. hereby covenant that TG Therapeutics, Inc. have the full right to convey the entire right, title, and interest herein assigned and that TG Therapeutics, Inc. have not executed and will not execute any agreement in conflict herewith.

IN WITNESS WHEREOF, TG THERAPEUTICS, INC. has caused this Assignment to be executed by its duly authorized representative:

TG THERAPEUTICS, INC.
Authorized by Hari Miskin

By:  I approve this document
30-Jan-2023 10:33:34 AM EST

Name: Hari Miskin
F635EAB53B2549818D91139FE1D93A8B

Title: Chief Development Officer

Date: 30-Jan-2023

Laboratoire Francais du Fractionnement et des Biotechnologies hereby accepts receipt of a joint and equal interest in the entire right, title, and interest in and to the patent applications described herein:


LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

By: 

Name: Rajesh SAGAR

Title: Head of IP and Legal Excellence

Date: December 20th 2022


S.A.
Tour W
102 Terrasse Boieldieu
19^{ème} Etage
92800 PUTEAUX - FRANCE
180 036 147 RCS NANTERRE